ArticleThe journal of liquid biopsy2026
A workflow for assessing antibody-drug conjugate target expression on circulating tumour cells from triple-negative breast cancer and epithelial ovarian cancer patients.
Article in The journal of liquid biopsy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antibody-drug conjugates (ADCs) are transforming the therapeutic landscape of solid tumours. Both patient selection and ADC efficacy in triple-negative breast cancer (TNBC) and epithelial ovarian cancer (EOC) are impacted by target antigen expression, which is often heterogeneous. Single tissue biopsies cannot capture this spatial heterogeneity, creating a need for real-time assessment to guide treatment. Circulating tumour cells (CTCs) may serve as minimally invasive biomarkers that can reflect ADC target expression. The aim of this study was to assess the detectability of clinically relevant ADC targets on CTCs in TNBC and EOC. Methods: ADC targets TROP-2 (TNBC) and FRα (EOC) were selected, along with emerging targets PD-L1 and CLDN6. Flow cytometry was used to characterise surface target antigen expression in three TNBC (MDA-MB-231, MDA-MB-468, HCC1937) and three EOC (SKOV3, OVCAR3, Kuramochi) cell lines. Cell spike-in assays using the Parsortix® system were performed to optimise in-cassette fixation and staining conditions, which were then applied to patient-derived samples for CTC enrichment and immunostaining. Results: Flow cytometry revealed heterogeneous antigen expression across cell lines. In TNBC, TROP-2 was uniformly expressed including in EpCAM-low MDA-MB-231 cells, whereas FRα was minimal or absent. PD-L1 was highly expressed in MDA-MB-231 and HCC1937 but low in MDA-MB-468. In EOC, FRα and TROP-2 were detectable in SKOV3 and OVCAR3 but low or absent in Kuramochi cells. Spike-in assays confirmed in-cassette detection of TROP-2, FRα, and PD-L1 following Parsortix® enrichment. In patient samples, TROP-2+ CTCs were identified in TNBC and FRα+ CTCs in EOC. Conclusion: This study demonstrates the feasibility of real-time ADC target assessment on CTCs using epitope-independent enrichment. TROP-2 shows additional utility for detecting CTCs with low EpCAM expression in TNBC. Incorporating ADC target markers into CTC workflows may enable monitoring of target expression, with potential to guide therapeutic decision-making in TNBC and EOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.